受容体相互作用タンパク質キナーゼ1（RIPK1）阻害薬の世界市場：対象患者、競合情勢、市場予測-2034年

主なハイライト

• 受容体相互作用タンパク質キナーゼ1（RIPK1）は炎症シグナルを制御し、アポトーシスとネクロプトーシスを誘導します。RIPK1キナーゼ活性の薬理学的阻害は、神経変性疾患、自己免疫疾患、炎症性疾患の動物モデルにおいて有効性が実証されています。
• RIPK1阻害剤は、関節リウマチや潰瘍性大腸炎などの治療薬として有効です。
• 現時点では、米国食品医薬品局（FDA）、欧州医薬品庁（EMA）を含む主要な保健当局から商業的使用の承認を受けたRIPK1阻害剤はありません。
• RIPK1阻害薬の開発には、Rigel PharmaceuticalsやEli Lilly（ocadusertib）、SanofiやDenali Therapeutics（eclitasertib）など複数の企業が携わっています。
• RIPK1阻害剤市場は、炎症性疾患や神経変性疾患におけるアンメットニーズに対応する可能性を秘めているが、初期段階の臨床試験で現在頓挫していることから、戦略的なパイプライン開拓と患者層別化の重要性が浮き彫りになっています。
• 全体として、自己免疫疾患やその他の適応症の治療開発に大きな可能性を秘めたエキサイティングなクラスです。今後数年間で現在の研究が成熟すれば、RIPK1阻害剤の理解が深まり、自己免疫疾患や神経変性疾患などの治療における役割が明確になると思われます。

当レポートは、米国、EU4ヶ国（ドイツ、フランス、イタリア、スペイン）、英国、日本におけるRIPK1阻害剤の歴史的、競合情勢、市場動向を詳細に調査・分析しています。

RIPK1阻害剤の市場レポートは、現在の治療法、新薬、個々の治療法の市場シェア、2020年から2034年までの主要7ヶ国のRIPK1阻害剤市場規模の現状と予測を提供します。また、現在のRIPK1阻害剤の治療法/アルゴリズム、アンメットメディカルニーズも網羅し、最良の機会を発掘し、市場の可能性を評価します。

対象地域

• 米国
• EU4ヶ国（ドイツ、フランス、イタリア、スペイン）および英国
• 日本

調査期間：2020年～2034年

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の理解と治療アルゴリズム

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の概要

RIPKタンパク質ファミリーの主要メンバーである受容体相互作用タンパク質キナーゼ1（RIPK1）は、細胞死と炎症反応の中心的なメディエーターとして機能し、細胞および組織の平衡を維持する上で重要な役割を果たしています。RIPK1のキナーゼ活性は、腫瘍壊死因子（TNF）に誘導されるネクローシスだけでなく、ネクロプトーシス（プログラムされた壊死細胞死）の制御において特に重要です。その結果、RIPK1は炎症と細胞生存を支配するいくつかのシグナル伝達経路に関与する極めて重要な上流制御因子として認識されるようになっています。特に、RIPK1は中枢神経系（CNS）内のすべての主要な細胞型で発現しています。RIPK1の標的阻害は、神経細胞を細胞死から保護する能力を示し、神経変性と神経炎症の両方を抑制することで治療効果をもたらす可能性があります。さらに、RIPK1のキナーゼドメインの構造的特徴から、選択的な低分子阻害剤の開発ターゲットとしても魅力的です。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤市場の概要

近年、関節リウマチや潰瘍性大腸炎など、様々な疾患に対するRIPK1阻害薬への関心が高まっています。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の疫学

当レポートのRIPK1阻害薬の疫学章では、米国、EU4ヶ国（ドイツ、フランス、イタリア、スペイン）、英国、日本を含む主要7ヶ国における2020年から2034年までのRIPK1阻害薬の特定適応症の総症例、RIPK1阻害薬の特定適応症の総適応患者数、RIPK1阻害薬の特定適応症の総治療症例として区分した疫学の過去および予測を提供します。

• 2024年における主要7ヶ国の関節リウマチ有病者数は約483万4,450人。
• EU4ヶ国と英国の中で潰瘍性大腸炎の症例数が最も多かったのはドイツ、次いで英国、最も少なかったのは2024年にイタリアで報告された症例数でした。
• 2024年に診断された潰瘍性大腸炎の有病者数は、日本が約32万8,500人でした。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の薬剤章

RIPK1阻害剤レポートの薬剤章では、初期および中期のRIPK1阻害剤の詳細な分析を掲載しています。また、RIPK1阻害剤の臨床試験の詳細、表現力豊かな薬理作用、契約と提携、承認、特許の詳細、含まれる各薬剤の利点と欠点、最新のニュースやプレスEli Lillyスの理解にも役立ちます。

新たな受容体相互作用タンパク質キナーゼ1（RIPK1）阻害薬

Ocadusertib（R552/LY3871801）- Rigel PharmaceuticalsとEli Lilly

Ocadusertibは、自己免疫疾患および炎症性疾患の治療薬として開発中の低分子化合物で、中枢神経系疾患に対する脳浸透性のRIPK1阻害薬です。前臨床試験において、R552はRIPK1を介した炎症と組織損傷のマウスモデルにおいて関節と皮膚の炎症の予防を示しました。同社は、中等度から重度の活動性の関節リウマチの成人患者を対象にocadusertibの第IIa相臨床試験（NCT05848258）を開始しました。この提携に基づき、Eli Lillyは中枢神経系疾患（アルツハイマー病および筋萎縮性側索硬化症[ALS]）を対象とした脳内浸透性RIPK1阻害剤の臨床開発もすべて主導します。RIPK1阻害剤は、TNFシグナル伝達と炎症性ネクロプトーシスの誘導において重要な役割を果たし、関節リウマチ、乾癬、IBDにおける幅広い可能性をサポートする可能性があり、その経験を持つEli LillyはRigel Pharmaceuticalsにとって理想的なパートナーです。

同社は2024年の年次プレゼンテーションで、約100人の患者を含む第IIa相試験の登録が進行中であり、2025年前半に予備的な結果が出る見込みであると述べています。

Eclitasertib（SAR443122/DNL758） - SanofiとDenali Therapeutics

RIPK1の低分子阻害剤であるEclitasertib（SAR443122）は、Denali Therapeuticsと共同開発中です。現在進行中の第II相RESOLUTE試験において、中等症から重症の潰瘍性大腸炎患者を対象とした有効性が評価されています。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤市場の展望

世界のRIPK1阻害剤市場は、自己免疫疾患の有病率の増加、強力な臨床パイプラインの活動、規制当局の承認拡大などを背景に、今後数年間で大幅な成長が見込まれます。

Rigel Pharmaceuticals、Eli Lilly、Sanofi、Denali Therapeuticsをはじめとする主要企業は、関節リウマチ、潰瘍性大腸炎など様々な適応症を対象としたRIPK1阻害剤の開発に積極的に取り組んでいます。初期段階の臨床試験では、皮膚エリテマトーデス（CLE）、急性移植片対宿主病（aGvHD）、アルツハイマー病、ALS、尋常性乾癬、多発性硬化症などの疾患に対するRIPK1阻害剤も検討されてきました。しかし、これらのプログラムの多くは、安全性の問題、限られた有効性、戦略的優先順位の変化などにより、初期段階で中止されたり、保留されたりしています。

AbbVieの低分子RIPK1阻害剤ABBV-668は潰瘍性大腸炎を対象として研究中でした。clinicaltrials.govによると、ABBV-668は2024年12月時点で潰瘍性大腸炎を対象とした第II相試験を終了していますが、その後の臨床開発に関する最新情報はなく、パイプラインにも存在しません。

また、RIPK1阻害剤に関する研究は主要7ヶ国以外でもいくつか実施されています。例えば、Accro BiosciencesのAC-003は現在aGvHD患者を対象とした第Ib相臨床試験中であり、中国では特発性肺線維症を対象とした試験も進行中です。さらにSIRONAXは、神経変性疾患、免疫疾患、炎症性疾患の治療薬としてSIR9900とSIR2446を開発しています。オーストラリア（Nucleus Network Pty Ltd.、オーストラリア、メルボルン）では、SIR9900を評価する最初のヒト臨床第I相試験が実施され、健康な成人および高齢者を対象に、SIR9900の経口単回投与（SAD）および反復投与（MAD）の安全性と忍容性が評価されました。

全体として、SIR9900は開発の大きな可能性を秘めたエキサイティングな新薬です。今後数年間で現在の研究が成熟すれば、RIPK1阻害剤の理解が深まり、自己免疫疾患における役割が明確になると思われます。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害薬の薬剤取り込み

本セクションでは、2025年から2034年の間に市場で上市される可能性のある承認済みおよび新興のRIPK1阻害剤の取り込み率に焦点を当てます。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害薬のパイプライン開発活動

当レポートでは、第II相および第I相段階にあるさまざまな治療薬候補に関する洞察を提供するとともに、標的治療薬の開発に携わる主要企業を分析しています。

さまざまな段階にある数多くの薬剤の存在は、予測期間中にRIPK1阻害剤市場の成長に大きな機会を生み出すと期待されています。

パイプライン開発活動

当レポートでは、RIPK1阻害剤治療薬に関する共同研究、買収・合併、ライセンシング、特許の詳細に関する情報を網羅しています。

KOLの見解

現在および将来の市場動向を把握するため、データのギャップを埋め、2次調査の妥当性を検証する1次調査を通じて、この領域で活躍する業界専門家の意見を取り入れています。RIPK1阻害剤の進化する治療状況、従来の治療法に対する患者の依存度、患者の治療法切り替えの受容性、薬剤の取り込み、アクセシビリティに関する課題などについての洞察を得るため、業界情勢に詳しい専門家にコンタクトを取りました。

定性分析

SWOT分析など、様々なアプローチを用いて定性・マーケットインテリジェンス分析を行います。SWOT分析では、疾患診断、患者意識、患者負担、競合情勢、費用対効果、治療法の地域的アクセスなどの観点から、強み、弱み、機会、脅威を提供します。これらの指摘は、患者負担、コスト分析、既存および発展途上の治療状況に関するアナリストの裁量と評価に基づいています。

市場参入と償還

償還とは、メーカーが市場に参入するための、メーカーと支払者との価格交渉のことを指します。高額なコストを削減し、必要不可欠な医薬品を手頃な価格にするために提供されます。医療技術評価（HTA）は、償還の意思決定や医薬品の使用推奨において重要な役割を果たしています。これらの推奨は、同じ医薬品であっても、主要7ヶ国市場で大きく異なります。

米国のヘルスケアシステムには、公的医療保険と民間医療保険の両方が含まれています。また、メディケアとメディケイドは米国最大の政府出資プログラムです。メディケア、継続医療教育（CME）プログラム、小児医療保険プログラム（CHIP）、州および連邦の医療保険マーケットプレースなどの主要ヘルスケアプログラムは、メディケア＆メディケイドサービスセンター（CMS）が監督しています。これら以外にも、Pharmacy Benefit Managers（PBMs）、サービスを提供する第三者機関、患者を支援する教育プログラムも存在します。

当レポートではさらに、国別のアクセシビリティと償還シナリオ、承認された治療法の費用対効果シナリオ、アクセシビリティを容易にし、自己負担費用をより安価にするプログラム、連邦政府または州政府の処方薬プログラムで保険に加入している患者に関する洞察などに関する詳細な洞察を提供しています。

このリストは、最終報告書に記載されるものであり、全てを網羅するものではありません。

調査範囲：

• 当レポートでは、主要イベント、エグゼクティブサマリー、RIPK1阻害剤の概要、メカニズム、治療法について解説しています。
• 競合情勢に関する包括的な考察、予測、治療率、薬剤の取り込み、薬剤情報の将来的な成長の可能性を提供しています。
• さらに、新たな治療法の包括的な説明と、後期段階および著名な治療法の詳細なプロファイルは、現在の状況に影響を与える見込みです。
• RIPK1阻害剤市場の詳細なレビュー、市場規模実績と予測、治療法別市場シェア、詳細な予測の前提条件、アプローチの根拠を記載しており、主要7ヶ国の薬剤をカバーしています。
• 当レポートは、主要7ヶ国 RIPK1阻害剤市場の形成と推進に役立つSWOT分析、専門家の洞察/KOLの見解、治療嗜好などの動向を理解することで、事業戦略を策定する際の優位性を提供します。

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のレポート洞察

• RIPK1阻害剤のターゲット患者群
• 治療アプローチ
• RIPK1阻害剤のパイプライン分析
• RIPK1阻害剤の市場規模および動向
• 既存および将来の市場機会

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤レポートの主要な強み

• 10年間の予測
• 主要7ヶ国のカバレッジ
• 主な競合
• 薬剤の取り込みと主な市場予測の前提条件

受容体相互作用タンパク質キナーゼ1（RIPK1）阻害薬レポートの評価

• 現在の治療法
• アンメットニーズ
• パイプライン製品プロファイル
• 市場の魅力
• 定性分析（SWOT）

目次

第1章 重要な洞察

第2章 報告書のイントロダクション

第3章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のエグゼクティブサマリー

第4章 主要な出来事

第5章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の疫学市場予測調査手法

第6章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤市場概要（主要7ヶ国）

• 2025年の治療法別市場シェア（％）分布
• 2034年の治療法別市場シェア（％）分布
• 2025年の適応症別市場シェア（％）分布
• 2034年の適応症別市場シェア（％）分布

第7章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤：背景と概要

• イントロダクション
• 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のさまざまな適応症における可能性
• 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の臨床応用

第8章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の対象患者

• 仮定と根拠
• 主な調査結果
• 主要7ヶ国における受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の適応症別総症例数
• 主要7ヶ国における受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の適応症別適格患者総数
• 主要7ヶ国における受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の適応症別治療可能症例数

第9章 新たな受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤

• 主な競合
• オカドゥセティブ（R552/LY3871801）：Rigel PharmaceuticalsとEli Lilly
• エクリタセルチブ（SAR443122/DNL758）：SanofiとDenali Therapeutics

第10章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤：主要7ヶ国市場分析

• 主な調査結果
• 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の市場展望
• 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のコンジョイント分析
• 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の主要市場予測の前提条件
• 主要7ヶ国における受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤の適応症別市場規模
• 米国
• EU4ヶ国と英国
• 日本

第11章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のSWOT分析

第12章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のKOL視点

第13章 受容体相互作用タンパク質キナーゼ1（RIPK1）阻害剤のアンメットニーズ

第14章 市場アクセスと償還

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in the 7MM (2020-2034)
• Table 9: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in the 7MM (2020-2034)
• Table 10: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in the United States (2020-2034)
• Table 12: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in the United States (2020-2034)
• Table 13: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in EU4 and the UK (2020-2034)
• Table 14: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in Japan (2020-2034)
• Table 16: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in the 7MM (2020-2034)
• Figure 3: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in the United States (2020-2034)
• Figure 6: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in EU4 and the UK (2020-2034)
• Figure 8: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size in Japan (2020-2034)
• Figure 10: Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• Receptor-interacting Protein Kinase 1 (RIPK1) regulates inflammatory signaling and induces apoptosis and necroptosis. Pharmacological inhibition of RIPK1 kinase activity has demonstrated efficacy in animal models of neurodegenerative, autoimmune and inflammatory diseases.
• RIPK1 inhibitors are effective treatments for rheumatoid arthritis, ulcerative colitis, and other indications.
• As of the current date, there are no RIPK1 inhibitors that have received regulatory approval for commercial use by major health authorities, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA).
• Several companies, including Rigel Pharmaceuticals and Eli Lilly (ocadusertib), Sanofi and Denali Therapeutics (eclitasertib), and others are engaged in the development of RIPK1 inhibitors.
• The RIPK1 inhibitor market holds potential in addressing unmet needs across inflammatory and neurodegenerative diseases, but current setbacks in early-stage trials highlight the importance of strategic pipeline development and patient stratification to unlock commercial viability.
• Overall, this is an exciting class that holds great potential for the development of treatment for autoimmune disorders and other indications. The maturation of current studies over the next few years will lead to a better understanding of RIPK1 Inhibitors and define their role in the therapy of autoimmune indications, neurodegenerative diseases, and others.

DelveInsight's "Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the RIPK1 inhibitors, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The RIPK1 inhibitors' market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM RIPK1 inhibitors' market size from 2020 to 2034. The report also covers current RIPK1 inhibitors' treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Understanding and Treatment Algorithm

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Overview

Receptor-Interacting Protein Kinase 1 (RIPK1), a key member of the RIPK protein family, serves as a central mediator of both cell death and inflammatory responses, thereby playing a vital role in sustaining cellular and tissue equilibrium. RIPK1's kinase activity is particularly important in orchestrating necroptosis-a programmed form of necrotic cell death-as well as Tumor Necrosis Factor (TNF)-induced necrosis. Consequently, RIPK1 has gained recognition as a pivotal upstream regulator involved in several signaling pathways that govern inflammation and cell survival. Notably, RIPK1 is expressed across all major cell types within the Central Nervous System (CNS). Targeted inhibition of RIPK1 has demonstrated the ability to protect neurons from cell death, offering potential therapeutic benefits by reducing both neurodegeneration and neuroinflammation. Moreover, the structural characteristics of RIPK1's kinase domain make it an attractive target for the development of selective small-molecule inhibitors.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Overview

In recent years, there has been a growing interest in the exploration of RIPK1 inhibitors for a variety disorders, encompassing rheumatoid arthritis, ulcerative colitis, and other indications.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Epidemiology

The epidemiology chapter RIPK1 inhibitors in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for RIPK1 inhibitors, total eligible patient pool in selected indications for RIPK1 inhibitors, and total treated cases in selected indications for RIPK1 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The prevalent cases of rheumatoid arthritis in 7MM in 2024 were nearly 4,834,450.
• Among the EU4 and the UK, Germany accounted for the highest number of cases of ulcerative colitis, followed by the UK and the lowest number of cases were reported in Italy in 2024.
• Japan accounted for nearly 328,500 diagnosed prevalent cases of ulcerative colitis in 2024.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Drug Chapters

The drug chapter segment of the RIPK1 inhibitors report encloses a detailed analysis of early and mid-stage RIPK1 inhibitors. It also helps understand the clinical trial details of RIPK1 inhibitors, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

Ocadusertib (R552/LY3871801): Rigel Pharmaceuticals and Eli Lilly

Ocadusertib, a small molecule being developed for the treatment of autoimmune and inflammatory disorders, and brain penetrating RIPK1 inhibitors for CNS diseases. In preclinical studies, R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage. The comapny had initiated a Phase IIa clinical trial (NCT05848258) studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis. Pursuant to the collaboration, Eli Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in CNS diseases (Alzheimer's disease and amyotrophic lateral sclerosis [ALS]). RIPK1 inhibitors play key role in TNF signaling and induction of pro-inflammatory necroptosis, which could support broad potential in rheumatoid arthritis, psoriasis and IBD, and with their experience, Lilly is the ideal partner for Rigel Pharmaceuticals.

In its 2024 annual presentation, the company stated that enrollment for the Phase IIa trial involving approximately 100 patients is ongoing and preliminary results are expected in the first half of 2025.

Eclitasertib (SAR443122/DNL758): Sanofi and Denali Therapeutics

Eclitasertib (SAR443122), a small-molecule inhibitor of RIPK1, is being co-developed in partnership with Denali Therapeutics. The ongoing Phase II RESOLUTE study is currently evaluating its efficacy in patients with moderate to severe ulcerative colitis.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Outlook

The global RIPK1 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical pipeline activity, and expanding regulatory approvals.

Several leading companies, including Rigel Pharmaceuticals, Eli Lilly, Sanofi, and Denali Therapeutics, are actively involved in the development of RIPK1 inhibitors for a range of indications such as rheumatoid arthritis, ulcerative colitis, and others. Early-stage clinical trials have also explored RIPK1 inhibitors for conditions like Cutaneous Lupus Erythematosus (CLE), Acute Graft versus Host Disease (aGvHD), Alzheimer's disease, ALS, plaque psoriasis, and multiple sclerosis. However, many of these programs were discontinued and kept on hold in early phases due to safety issues, limited efficacy, or shifting strategic priorities.

ABBV-668, AbbVie's small molecule RIPK1 inhibitor, was under investigation for ulcerative colitis. As per the clinicaltrials.gov ABBV-668 has completed its Phase II trial in ulcerative colitis as of December 2024, while there is no update regarding its clinical development since then and the product is not present in the pipeline.

In addition, several studies on RIPK1 inhibitors have been conducted outside the 7MM. For instance, AC-003 by Accro Biosciences is currently in a Phase Ib clinical trial for patients with aGvHD and is also under investigation for Idiopathic Pulmonary Fibrosis in China. Furthermore, SIRONAX is developing SIR9900 and SIR2446 for the treatment of neurodegenerative, immune, and inflammatory disorders. First-in-human, Phase I study to evaluate SIR9900 was conducted in Australia (Nucleus Network Pty Ltd. Melbourne, Australia) to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of oral SIR9900 in healthy adult and elderly participants.

Overall, this is an exciting new class with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of RIPK1 inhibitors and define their role in autoimmune indications.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging RIPK1 inhibitors expected to be launched in the market during 2025-2034.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for RIPK1 inhibitors market growth over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for RIPK1 inhibitor therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on RIPK1 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Duke University School of Medicine, and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or RIPK1 inhibitors' market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the RIPK1 inhibitors, explaining its mechanism, and therapies.
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the RIPK1 inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM RIPK1 inhibitors market.

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Report Insights

• RIPK1 Inhibitors Targeted Patient Pool
• Therapeutic Approaches
• RIPK1 Inhibitors Pipeline Analysis
• RIPK1 Inhibitors Market Size and Trends
• Existing and future Market Opportunities

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What was the total market size of RIPK1 inhibitors, the market size by therapies, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for RIPK1 inhibitors?
• What are the pricing variations among different geographies for approved therapies?
• What are the risks, burdens, and unmet needs of treatment with RIPK1 inhibitors? What will be the growth opportunities across the 7MM for the patient population of RIPK1 inhibitors?
• What are the key factors hampering the growth of the market for RIPK1 inhibitors?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for RIPK1 inhibitors?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the RIPK1 inhibitors market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

4. Key Events

5. Epidemiology Market Forecast Methodology of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

6. Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2034
• 6.3. Market Share (%) Distribution by Indications in 2025
• 6.4. Market Share (%) Distribution by Indications in 2034

7. Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors: Background and Overview

• 7.1. Introduction
• 7.2. Potential of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in Different Indications
• 7.3. Clinical Applications of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

8. Target Patient Pool of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

• 8.1. Assumptions and Rationale
• 8.2. Key Findings
• 8.3. Total Cases of Selected Indication for Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in the 7MM
• 8.4. Total Eligible Patient Pool of Selected Indication for Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in the 7MM
• 8.5. Total Treatable Cases in Selected Indication for Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in the 7MM

9. Emerging Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

• 9.1. Key Competitors
• 9.2. Ocadusertib (R552/LY3871801): Rigel Pharmaceuticals and Eli Lilly
  • 9.2.1. Product Description
  • 9.2.2. Other Developmental Activities
  • 9.2.3. Clinical Development
  • 9.2.4. Safety and Efficacy
  • 9.2.5. Analyst Views
• 9.3. Eclitasertib (SAR443122/DNL758): Sanofi and Denali Therapeutics
  • 9.3.1. Product Description
  • 9.3.2. Other Developmental Activities
  • 9.3.3. Clinical Development
  • 9.3.4. Safety and Efficacy
  • 9.3.5. Analyst Views

10. Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors: Seven Major Market Analysis

• 10.1. Key Findings
• 10.2. Market Outlook of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors
• 10.3. Conjoint Analysis of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors
• 10.4. Key Market Forecast Assumptions of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors
  • 10.4.1. Cost Assumptions and Rebates
  • 10.4.2. Pricing Trends
  • 10.4.3. Analogue Assessment
  • 10.4.4. Launch Year and Therapy Uptakes
• 10.5. Total Market Sizes of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Indications in the 7MM
• 10.6. The United States
  • 10.6.1. Total Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in the United States
  • 10.6.2. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Indication in the United States
  • 10.6.3. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Therapies in the United States
• 10.7. EU4 and the UK
  • 10.7.1. Total Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in EU4 and the UK
  • 10.7.2. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Indications in EU4 and the UK
  • 10.7.3. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Therapies in EU4 and the UK
• 10.8. Japan
  • 10.8.1. Total Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors in Japan
  • 10.8.2. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Indications in Japan
  • 10.8.3. Market Size of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors by Therapies in Japan

11. SWOT Analysis of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

12. KOL Views of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

13. Unmet Needs of Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors

14. Market Access and Reimbursement

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight